Jeligo

Linagliptin, the active ingredient in Jeligo, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Jeligo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established logistics and regulatory expertise to ensure reliable delivery across multiple markets, and consistent quality assurance for patient safety.

Jeligo (linagliptin) is used within the antidiabetic drug class to manage blood glucose levels in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control as part of a comprehensive treatment plan. - Adjunct therapy: used together with other antidiabetic agents to achieve target HbA1c. - Combination with metformin: provides enhanced glucose lowering when both agents are prescribed. - Renal impairment: can be used without dose adjustment in patients with mild to moderate renal dysfunction.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient pain in the head region. - Gastrointestinal upset: includes nausea, abdominal discomfort, or diarrhea. - Dizziness: occasional sensation of light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: such as rash, angioedema, or anaphylaxis. - Bullous pemphigoid: rare skin disorder characterized by blistering lesions.

Before initiating therapy, consider the following precautions.

- Renal function monitoring: assess baseline and periodic kidney function. - Hepatic assessment: evaluate liver enzymes in patients with liver disease. - Pancreatitis vigilance: educate patients to report persistent abdominal pain. - Hypoglycemia risk: review concomitant use of insulin or sulfonylureas. - Patient education: instruct on recognizing signs of allergic reactions. - Store at room temperature: keep in the original pack, protect from moisture.

Linagliptin may interact with other medicines; review the following.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure. - Combination with insulin or sulfonylureas: increased risk of hypoglycemia. - Strong P‑gp inhibitors (e.g., itraconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: monitor electrolytes and blood pressure. - ACE inhibitors: observe for potential additive blood pressure effects. - Warfarin: check INR values periodically for any alteration.